Advertisement

Benign Prostatic Hyperplasia

Innovations in Management

  • Zbigniew Petrovich
  • Luc Baert

Table of contents

  1. Front Matter
    Pages I-XII
  2. Glenn B. Mieszkalski, Joan Keit, Luther W. Brady
    Pages 39-48
  3. Paola Dal Cin, Herman Van Den Berghe
    Pages 49-56
  4. Reginald C. Bruskewitz, Morten Riehmann
    Pages 65-76
  5. Raymond H. Oyen
    Pages 77-139
  6. Hendrik Vandeursen, Hein Van Poppel, Luc Baert
    Pages 157-165
  7. Morten Riehmann, Reginald C. Bruskewitz
    Pages 167-174
  8. Ken Anson, Graham Watson
    Pages 175-191
  9. Christopher M. Dixon, Herbert Lepor
    Pages 193-204
  10. Melvin A. Astrahan, Piotr S. Debicki
    Pages 205-237
  11. Stanislaw Szmigielski, Bronislaw Stawarz, Zbigniew Petrovich
    Pages 275-289
  12. Karl Horst Bichler, W. L. Strohmaier, W. Mattauch
    Pages 291-302
  13. Marian Devonec, Jean-Philippe Fendler, Patrice Joubert, Paul Perrin
    Pages 303-315
  14. Back Matter
    Pages 375-384

About this book

Introduction

A symposium on benign prostatic hyperplasia is appropriate at a time when new knowledge and new technology are rapidly emerging. As the age of the population has increased and diagnostic methods have improved, the incidence of diseases of the prostate has increased. Benign prostatic hyperplasia (BPH) is the most common benign tumor in men and results in urinary symptoms in the majority of men older than 50 years; furthermore it has in the past necessitated operative intervention in 20%-30% of men who live to the age of 80 years. The relief of obstruction resulting from this benign neoplasm by means of transurethral resection (TURP) or surgical enucleation represented a major advance and helped to establish urology as a major surgical science. Over the years, urologists became more and more proficient with the resectoscope, reducing the need for open surgery, and over time more procedures were done for more modest symptoms. Although unquestionably effective in the relief of bladder outlet obstruction in the majority of men treated, TURP has not been without morbidity. In 1989, the American Urological Association (AUA) reported an 18% im­ mediate postoperative morbidity in its cooperative study of 13 participating institutions evaluating 3885 patients (MEBUST et al. 1989). Included were patients requiring transfusion, those experiencing excessive absorption of irrigating fluids ("TUR syndrome"), those experiencing myocardial arrhythmias, and a few suffer­ ing myocardial infarction.

Keywords

Laser Prostataerkrankung Prostatahyperplasia Urologie benign prostatic hyperplasia geriatrics pathology patients pharmacology prostate prostatectomy surgery therapeutic options treatment urology

Editors and affiliations

  • Zbigniew Petrovich
    • 1
  • Luc Baert
    • 2
    • 3
  1. 1.Department of Radiation Oncology, Kenneth Norris Jr. Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of Urology, St. Pieter’s HospitalCatholic University of LeuvenLeuvenBelgium
  3. 3.School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-78185-8
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-78187-2
  • Online ISBN 978-3-642-78185-8
  • Buy this book on publisher's site